Based on the wording in the PR, it’s reasonable to infer that the median survival time in the control arm will indeed stay at 16.9 months. However, this in itself doesn’t mean much because it’s the hazard ratio—not the median value in the two arms—that will ultimately determine whether this trial is considered a success.
I think that's where I'm falling off the wagon just because I assumed that if we know that the minimum median survival for the OGX-011 arm is 22.7 months, as stated in the PR, and if we could infer that the median survival would be 16.9 months for the control, then you have at least a difference of almost 6 months in favor of the OGX-011 arm. I assumed that would be great news.
If you can expand any on why it's the hazard ratio, and not those median value differences, that really matters, I'd greatly appreciate it.
Market Data 
Markets 
AI
